BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29220734)

  • 21. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
    Roche S; McMahon G; Clynes M; O'Connor R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(31):3982-90. PubMed ID: 19854117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run.
    van Veelen A; van Geel R; Schoufs R; de Beer Y; Stolk LM; Hendriks LEL; Croes S
    Biomed Chromatogr; 2021 Dec; 35(12):e5224. PubMed ID: 34363425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of a sensitive LC-MS/MS method for simultaneous determination of eight tyrosine kinase inhibitors and its application in mice pharmacokinetic studies.
    He Y; Zhou L; Gao S; Yin T; Tu Y; Rayford R; Wang X; Hu M
    J Pharm Biomed Anal; 2018 Jan; 148():65-72. PubMed ID: 28965046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS.
    Krens SD; van der Meulen E; Jansman FGA; Burger DM; van Erp NP
    Biomed Chromatogr; 2020 Mar; 34(3):e4758. PubMed ID: 31758580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma.
    Vrobel I; Janečková H; Faber E; Bouchalová K; Mičová K; Friedecký D; Adam T
    Ther Drug Monit; 2016 Aug; 38(4):516-24. PubMed ID: 27414975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.
    Herbrink M; de Vries N; Rosing H; Huitema ADR; Nuijen B; Schellens JHM; Beijnen JH
    Biomed Chromatogr; 2018 Apr; 32(4):. PubMed ID: 29165815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.
    Moreno JM; Wojnicz A; Steegman JL; Cano-Abad MF; Ruiz-Nuño A
    Biomed Chromatogr; 2013 Apr; 27(4):502-8. PubMed ID: 23034891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a Sensitive and High-Throughput Assay for Simultaneous Quantification of 5 Tyrosine Kinase Inhibitors and 2 Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry.
    Sumimoto T; Nakahara R; Suzuki Y; Tanaka R; Yoshida N; Ogata M; Itoh H
    Ther Drug Monit; 2022 Jun; 44(3):419-429. PubMed ID: 34469417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative pharmacokinetic profiles of selected irreversible tyrosine kinase inhibitors, neratinib and pelitinib, with apigenin in rat plasma by UPLC-MS/MS.
    Maher HM; Alzoman NZ; Shehata SM; Abahussain AO
    J Pharm Biomed Anal; 2017 Apr; 137():258-267. PubMed ID: 28167419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.
    Birch M; Morgan PE; Handley S; Ho A; Ireland R; Flanagan RJ
    Biomed Chromatogr; 2013 Mar; 27(3):335-42. PubMed ID: 22886846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry.
    Chahbouni A; den Burger JC; Vos RM; Sinjewel A; Wilhelm AJ
    Ther Drug Monit; 2009 Dec; 31(6):683-7. PubMed ID: 19865001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
    Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
    Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study.
    Zheng N; Zhao C; He XR; Jiang ST; Han SY; Xu GB; Li PP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Feb; 1011():215-22. PubMed ID: 26795401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-throughput quantification of 8 antihypertensive drugs and active metabolites in human plasma using UPLC-MS/MS.
    van der Nagel BCH; Versmissen J; Bahmany S; van Gelder T; Koch BCP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():367-373. PubMed ID: 28666228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification of eight hematological tyrosine kinase inhibitors in both plasma and whole blood by a validated LC-MS/MS method.
    Verougstraete N; Stove V; Verstraete AG; Stove C
    Talanta; 2021 May; 226():122140. PubMed ID: 33676691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.
    Rousset M; Titier K; Bouchet S; Dutriaux C; Pham-Ledard A; Prey S; Canal-Raffin M; Molimard M
    Clin Chim Acta; 2017 Jul; 470():8-13. PubMed ID: 28412197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isotope dilution direct injection mass spectrometry method for determination of four tyrosine kinase inhibitors in human plasma.
    Mičová K; Friedecký D; Faber E; Adam T
    Talanta; 2012 May; 93():307-13. PubMed ID: 22483915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of geniposide in adjuvant arthritis rat plasma by ultra-high performance liquid chromatography tandem mass spectrometry method and its application to oral bioavailability and plasma protein binding ability studies.
    Chen J; Wu H; Xu GB; Dai MM; Hu SL; Sun LL; Wang W; Wang R; Li SP; Li GQ
    J Pharm Biomed Anal; 2015 Apr; 108():122-8. PubMed ID: 25771205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
    Blanchet B; Saboureau C; Benichou AS; Billemont B; Taieb F; Ropert S; Dauphin A; Goldwasser F; Tod M
    Clin Chim Acta; 2009 Jun; 404(2):134-9. PubMed ID: 19341717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-throughput assay for quantification of the plasma concentrations of thiopental using automated solid phase extraction (SPE) directly coupled to LC-MS/MS instrumentation.
    Moosavi SM; Shekar K; Fraser J; Smith MT; Ghassabian S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1038():80-87. PubMed ID: 27802918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.